Tech that

2025 in life sciences – building real foundations beyond the hype

The life sciences industry is heading into 2025 with a distinct shift in mindset. Unlike previous years, marked by speculative predictions and hyped technologies, the upcoming year promises a more grounded approach.

Life sciences organisations are expected to make substantial investments in modernising their technology stacks, not just in capturing attention with AI and digital transformation buzzwords, but in building practical solutions that address the sector’s unique complexities.

From deeper investments in flexible, interoperable technology platforms, to a stronger embrace of hybrid and open-source models, the year ahead is about ensuring life sciences organisations are ready to scale innovation sustainably and responsibly.

Next year we’re likely to see a focused commitment to modernising tech systems. For years, life sciences organisations have operated on infrastructure that struggles to meet today’s demands for speed, integration and security.

The upcoming year will push companies toward revamping their technology stacks, with a focus on cloud solutions, advanced data analytics and interoperability.

This movement is driven not by hype but by a pressing need for real infrastructure change to support innovations like personalised medicine, AI-driven insights and predictive analytics that are reshaping patient care.

Crucially, companies will avoid committing to rigid technology stacks, recognising that adaptability is key. They’re expected to prioritise a more flexible, hybrid approach to IT, integrating best-in-class tools from both proprietary and open-source platforms.

This hybrid approach allows organisations to keep pace with new advancements without being locked into a single, monolithic system, ensuring they can respond to emerging challenges and opportunities effectively.

Generative AI (GenAI) has undeniably stirred interest across industries, and life sciences is no exception. However, while the technology’s potential to drive insights and innovation is evident, organisations are moving away from superficial AI integration.

In 2025, the emphasis will shift from ‘what GenAI can do’ to ‘how it’s being used,’ focusing on areas like enhanced data processing, targeted diagnostics and efficient drug discovery. Instead of exploring GenAI’s possibilities in the abstract, life sciences companies are likely to prioritise measurable use cases that deliver clear value.

At the same time, investments in GenAI will involve careful consideration of data governance, security and ethical implications. As we continue to integrate AI in patient-centric processes, issues around privacy, fairness and transparency will demand attention.

The convergence between life sciences, healthcare and tech sectors will continue to deepen, blurring traditional boundaries and fostering new partnerships.

In 2025, collaboration across these sectors is expected to become more strategic, focusing on seamless data integration and shared goals.

Pharmaceutical companies, hospitals, tech firms and regulators are increasingly finding common ground to develop solutions that span patient care, drug discovery and healthcare delivery.

One of the major hurdles remains interoperability – the ability to share data securely and effectively across systems.

As organisations push toward a more connected, patient-centred healthcare ecosystem, 2025 will see heightened focus on solving interoperability challenges.

Investment in secure data exchange and collaborative frameworks will be critical, enabling real-time insights that improve patient outcomes and reduce operational inefficiencies.

As life sciences companies become more technologically driven, a parallel focus on ethical considerations is imperative.

The industry’s use of AI, automation and data analytics holds immense promise, but ethical considerations around data privacy, algorithmic fairness and bias will need careful navigation.

Companies are under increasing pressure to ensure that their technological advancements do not inadvertently compromise patient trust or widen health disparities. 2025 marks a transition from hypothetical advancements to meaningful investments.

Life sciences companies are not focused on capturing headlines but on implementing the necessary technology upgrades and partnerships to build a resilient, adaptable infrastructure.

Alyssa Farrell Life Sciences Director, Global Health and Life Sciences Industry Marketing, SAS.
Go to sas.com